508 related articles for article (PubMed ID: 34831439)
1. Signaling through the S1P-S1PR Axis in the Gut, the Immune and the Central Nervous System in Multiple Sclerosis: Implication for Pathogenesis and Treatment.
Chatzikonstantinou S; Poulidou V; Arnaoutoglou M; Kazis D; Heliopoulos I; Grigoriadis N; Boziki M
Cells; 2021 Nov; 10(11):. PubMed ID: 34831439
[TBL] [Abstract][Full Text] [Related]
2. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
Pérez-Jeldres T; Alvarez-Lobos M; Rivera-Nieves J
Drugs; 2021 Jun; 81(9):985-1002. PubMed ID: 33983615
[TBL] [Abstract][Full Text] [Related]
3. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Hla T; Brinkmann V
Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
[TBL] [Abstract][Full Text] [Related]
4. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.
Tsai HC; Han MH
Drugs; 2016 Jul; 76(11):1067-79. PubMed ID: 27318702
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems.
Healy LM; Antel JP
Curr Drug Targets; 2016; 17(16):1841-1850. PubMed ID: 26424391
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Chun J; Giovannoni G; Hunter SF
Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
[TBL] [Abstract][Full Text] [Related]
8. The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives.
Lucaciu A; Brunkhorst R; Pfeilschifter JM; Pfeilschifter W; Subburayalu J
Cells; 2020 Jun; 9(6):. PubMed ID: 32580348
[TBL] [Abstract][Full Text] [Related]
9. A Sphingosine 1-Phosphate Gradient Is Linked to the Cerebral Recruitment of T Helper and Regulatory T Helper Cells during Acute Ischemic Stroke.
Lucaciu A; Kuhn H; Trautmann S; Ferreirós N; Steinmetz H; Pfeilschifter J; Brunkhorst R; Pfeilschifter W; Subburayalu J; Vutukuri R
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872326
[TBL] [Abstract][Full Text] [Related]
10. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.
Soliven B; Miron V; Chun J
Neurology; 2011 Feb; 76(8 Suppl 3):S9-14. PubMed ID: 21339490
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
Roy R; Alotaibi AA; Freedman MS
CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
[TBL] [Abstract][Full Text] [Related]
12. Lessons from S1P receptor targeting in multiple sclerosis.
Colombo E; Farina C
Pharmacol Ther; 2022 Feb; 230():107971. PubMed ID: 34450231
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine-1-Phosphate Signaling in Immune Cells and Inflammation: Roles and Therapeutic Potential.
Aoki M; Aoki H; Ramanathan R; Hait NC; Takabe K
Mediators Inflamm; 2016; 2016():8606878. PubMed ID: 26966342
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement.
Bordet R; Camu W; De Seze J; Laplaud DA; Ouallet JC; Thouvenot E
Rev Neurol (Paris); 2020; 176(1-2):100-112. PubMed ID: 31757428
[TBL] [Abstract][Full Text] [Related]
15. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
[TBL] [Abstract][Full Text] [Related]
16. Impact of sphingosine 1-phosphate modulation on immune outcomes.
Pinschewer DD; Brinkmann V; Merkler D
Neurology; 2011 Feb; 76(8 Suppl 3):S15-9. PubMed ID: 21339486
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
18. Unveiling the biological role of sphingosine-1-phosphate receptor modulators in inflammatory bowel diseases.
Tourkochristou E; Mouzaki A; Triantos C
World J Gastroenterol; 2023 Jan; 29(1):110-125. PubMed ID: 36683721
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
McGinley MP; Cohen JA
Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
[TBL] [Abstract][Full Text] [Related]
20. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
